华海药业：收到3种药品的药品注册证书

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of three drugs, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Drug Approvals - The company has obtained drug registration certificates for injectable cytarabine, agomelatine tablets, and controlled-release cabergoline [1] - Injectable cytarabine is indicated for the induction and maintenance treatment of acute non-lymphocytic leukemia in adults and children [1] - Agomelatine tablets are used for the treatment of major depressive disorder in adults [1] - Controlled-release cabergoline is indicated for the treatment of primary Parkinson's disease and post-encephalitic Parkinson's syndrome [1]